Classification of PD‐L1 expression in various cancers and macrophages based on immunohistocytological analysis

Programmed death (PD)‐1/PD‐ligand 1 (PD‐L1) antibodies have shown an intense clinical effect in some patients with PD‐L1(+) tumors, and their applications have rapidly expanded to various cancer types with or without the application of new companion diagnostics (CDx) with a lower cutoff value and in...

Descripción completa

Detalles Bibliográficos
Autores principales: Saito, Yoichi, Fujiwara, Yukio, Shinchi, Yusuke, Mito, Remi, Miura, Yuji, Yamaguchi, Tomoya, Ikeda, Koei, Urakami, Shinji, Nakashima, Yuta, Sakagami, Takuro, Suzuki, Makoto, Tabata, Yasuhiko, Komohara, Yoshihiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9459416/
https://www.ncbi.nlm.nih.gov/pubmed/35633190
http://dx.doi.org/10.1111/cas.15442

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9459416/
https://www.ncbi.nlm.nih.gov/pubmed/35633190
http://dx.doi.org/10.1111/cas.15442

Ejemplares similares